Literature DB >> 15550254

Treatment of acute vivax malaria with tafenoquine.

Peter Nasveld1, Scott Kitchener.   

Abstract

Tafenoquine is an 8-aminoquiniline related to primaquine with pre-clinical activity against a range of malaria species. We treated two acute cases of vivax malaria with tafenoquine (800 mg over three days) alone, instead of conventional chloroquine (1500 mg over three days) and primaquine (420 mg over 14 days). In addition to the convenience of this regimen, the rapid parasite clearances observed, coupled with a good clinical response and lack of recrudescence or relapse, indicate that further investigation of tafenoquine in the treatment of vivax malaria is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15550254     DOI: 10.1016/j.trstmh.2004.01.013

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  9 in total

1.  Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

Authors:  Moritz Treiber; Gunther Wernsdorfer; Ursula Wiedermann; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

2.  Synthesis, Molecular Docking, In Silico ADME Predictions, and Toxicity Studies of N-Substituted-5-(4-Chloroquinolin-2-yl)-1,3,4-Thiadiazol-2-Amine Derivatives as COVID-19 Inhibitors.

Authors:  Walaa S El-Serwy; Weam S El-Serwy
Journal:  Russ J Bioorg Chem       Date:  2021-03-20       Impact factor: 0.796

Review 3.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

4.  Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).

Authors:  Geoffrey S Dow; Montip Gettayacamin; Pranee Hansukjariya; Rawiwan Imerbsin; Srawuth Komcharoen; Jetsumon Sattabongkot; Dennis Kyle; Wilbur Milhous; Simon Cozens; David Kenworthy; Anne Miller; Jim Veazey; Colin Ohrt
Journal:  Malar J       Date:  2011-07-29       Impact factor: 2.979

5.  Crystal structure of bis-{μ-(E)-2-[(2-oxido-phenyl-imino)-meth-yl]quinolin-8-olato-κ4O,N,N',O'}bis-[di-butyl-tin(IV)].

Authors:  Camacho-Camacho Carlos; Ortiz-Pastrana Naytzé; Garza-Ortiz Ariadna; Rojas-Oviedo Irma
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-01-01

Review 6.  The global pipeline of new medicines for the control and elimination of malaria.

Authors:  Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

7.  Crystal structure of 2-(4-methyl-piperazin-1-yl)quinoline-3-carbaldehyde.

Authors:  R Nivedita Desai; S Sreenivasa; S Naveen; N K Lokanath; P A Suchetan; D B Aruna Kumar
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-10-31

Review 8.  Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Authors:  Yehenew A Ebstie; Solomon M Abay; Wondmagegn T Tadesse; Dawit A Ejigu
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162

9.  Tafenoquine for travelers' malaria: evidence, rationale and recommendations.

Authors:  J Kevin Baird
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.